Summary Ninety-four human non-small cell lung carcinomas (NSCLC) of previously untreated patients were analysed for the presence of P-glycoprotein (P-170) and glutathione S-transferase-n (GST-i) by means of immunohistochemistry. The expression of P-170 and GST-ir was compared with the results of doxorubicin resistance of the tumours in vitro and the smoking habits of the patients. A significant relationship between smoking habits of the patients and resistance of NSCLC was found (P = 0.007). Of the 72 tumours of smokers 57 (= 79%) were resistant, whereas of the 22 tumours of non-smokers only 11 ( = 50%) showed resistance. Identical results were obtained when the analysis was restricted to patients with epidermoid lung carcinomas (P = 0.004). In contrast to these data, there exists no relationship between resistance and smoking for adenocarcinomas of the lung.
During the past few years the phenomenon of multidrugresistance (MDR) has been thoroughly analysed and some of its molecular aspects clarified. The MDR-phenotype is characterised by cross-resistance between hydrophobic compounds without structural or functional similarities. The connection between MDR and the expression of a 170 kDa membrane glycoprotein (P-glycoprotein) has been clearly established in different tumour models (Riordan et al., 1985) . The most direct evidence of the role of the P-glycoprotein (P-170) in resistance has come from studies that have demonstrated that resistance can be conferred through transfer of genetic material encoding P-glycoprotein (Gros et al., 1986; Sugimoto & Tsuruo, 1987) . However, not all resistant tumours overexpress P-170 and refractoriness to chemotherapy can only partly be explained by P-170. Batist et al. (1986) described an elevated expression of glutathione S-transferase-ic (GST-i ) in doxorubicin-resistant MCF-7 cells. Alterations in nuclear DNA topoisomerase II (Topo II) content have been also reported in doxorubicin-resistant P388 cells (Deffie et al., 1989) . Interestingly, Fairchild et al. (1987) observed an overexpression of both P-170 and GST-i in doxorubicinresistant MCF-7 cells. This raises the question as to whether the expression of those two proteins may be under a common regulatory control.
In an earlier study with 160 human lung tumours (Volm et al., 1990a) we demonstrated that there is a significant relationship between smoking and response to doxorubicin in vitro. Carcinomas of smokers tended to be resistant more frequently than carcinomas of non-smokers. Until now the mechanisms for the resistance of lung tumours are unknown. Therefore, we have analysed non-small cell lung carcinomas (NSCLC) of previously untreated patients for the presence of P-170 and GST-i by immunohistochemistry, a method which we have found useful for detection of P-170 in the past with different human tumours (Volm et al., 1988a; Schneider et al., 1989; Bak et al., 1990) . The current paper include 94 NSCLC of the earlier study (Volm et al., 1990a) (Carr & Mountain, 1977 
Immunohistochemistry
For detection of P-170 and GST-x the biotin-streptavidinperoxidase method described previously was used (Volm et al., 1988a were used. The antibody against GST-ic was developed against the rat isoenzyme GST-P (Satoh et al., 1985) . Since rat GST-P and human GST-i isoenzymes share 85% amino acid sequence homology (Morrow et al., 1989) we conclude that this antibody detects GST-ir in human lung cancers. After three washing steps with PBS the cells were incubated with biotinylated sheep anti-mouse IgG (Amersham, Braunschweig, Germany) for detection of P-170 and donkey antirabbit IgG (Amersham) for detection of GST-7 , and Topo II (30min, dilution: 1:50 with 5% normal human serum). Afterwards, the streptavidin-biotinylated peroxidase complex (Amersham, 1:100, 30min) was added. Peroxidase activity was visualised with 3-amino-9-ethylcarbazole (5-10 min) which gives a red-brown reaction product. Counterstaining was performed with haematoxylin and the sections were mounted with glycerol gelatin. Negative controls were done omitting the primary antibodies. Endogenous peroxidase activity of biopsy sections was quenched using 0.5% H202. Furthermore unspecific binding sites were blocked by incubation with normal sheep serum (P-170) and normal donkey serum (GST-ir , Topo II), respectively (dilution 1: 10, 10 min, Dianova). In addition, endogenous biotin may lead to potential problems in the application of streptavidin-based detection systems, therefore, unlabelled streptavidin (Amersham) was preincubated to suppress endogenous biotin-activity (dilution 1:50, 10min). Because positive immunostaining was not only found in malignant cell populations but also in macrophages (Schlaifer et al., 1990) we distinguished between tumour cells and macrophages using Mab CD68 (DAKO-CD68, KP1, Dakopatts, Copenhagen, Denmark 11   12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48   Stage   II  I  III  III  III  III  I  III  III  I  III  I  III  III  III  II  II  I   I   III  III   III   III  II  III  III  III  III   III   III  II   III   III   III   II   III   III   III   I  III  III  III  III  III   III   III  I 
Results
In the present study, 94 human non-small cell lung carcinomas (NSCLC) of previously untreated patients were analysed for the presence of P-glycoprotein (P-170) and glutathione S-transferase-i (GST-i ) by means of immunohistochemistry. Clinical data of the patients and characteristics of the tumours are given in Table I . In Table II to Table  IV the immunohistochemical data are listed together with the results of resistance of the tumours in vitro and the smoking habits of the patients. Of the 48 patients with epidermoid lung carcinomas, 38 were smokers and 10 non-smokers (Table II) . Of the 48 tumours, 39 ( = 81%) were resistant and nine (= 19%) were sensitive to doxorubicin in the test. Twenty-four tumours ( = 50%) showed positivity for P-170 and 33 (= 69%) for GST-ir 9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34   Stage   II   III  III  III  III  III  I  III  III  III  III  III  I  III  III  III  III  I  III  III   III  III   II   III  III  III  III  III  III Of the 34 patients with adenocarcinomas, 22 were smokers and 12 were non-smokers (Table III) . Eighteen out of 34 tumours showed resistance in vitro (= 59%) whereas 16 tumours (= 41%) were sensitive. Eleven tumours (= 32%) were positive for P-170 and 16 ( = 47%) for GST-i . All 12 patients with large cell carcinomas of the lung were smokers (Table IV) . All tumours except one showed resistance in vitro. Nine tumours (= 75%) showed expression of P-170 and ten ( = 83%) expression of GST-c . In order to examine whether a relationship exists between smoking habits of patients, resistance of tumours in vitro, and expression of P-170 or GST-7c , we analysed the data by Fisher exact test. We found a significant relationship between smoking habits of the patients with NSCLC and resistance in vitro (P = 0.007) ( Table V) . Carcinomas of smokers were more frequently resistant than carcinomas of non-smokers. Of the 72 non-small cell lung carcinomas of smokers, 57 (= 79%) were resistant, whereas of the 22 tumours of nonsmokers only 11 ( = 50%) showed resistance. This relationship is more apparent for the epidermoid lung carcinomas. Of the 38 tumours of smokers, 34 (= 89%) were resistant and of the ten tumours of non-smokers only five tumours (= 50%) were resistant (P = 0.004). In contrast to these data, there exists no relationship between resistance and smoking for adenocarcinomas of the lung. This may be expected because adenocarcinomas are said to be less frequently associated with smoking than are epidermoid lung carcinomas.
The relationship between expression of P-170 and GST-ic, respectively and smoking habits of the patients, is also shown in Table V . Forty-two ( = 58%) out of 72 non-small cell lung carcinomas of smokers showed expression of P-170, whereas out of 22 tumours of non-smokers only two ( = 9%) revealed P-170 expression. This relationship is significant (P <0.0001). A similar significant relationship was found for epidermoid carcinomas (P =0.004) and adenocarcinomas (P = 0.027). Fifty NSCLC (= 69%) of smokers out of 72 tumours revealed strong expression of GST-ir. In contrast, only nine ( = 41%) out of 22 NSCLC of non-smokers showed GST-n expression. The relationship between smoking habits of the patients and overexpression of GST-7 is significant (P = 0.015). Similar results are obtained when the analysis is restricted to just those patients with epidermoid lung carcinomas and adenocarcinomas of the lung, but the results are not significant (Table V) . We found significant correlations between resistance measured in vitro and expression of P-170 (P<0.0001) or expression of GST-(P<0.0001) (Table VI) .
Moreover, we correlated the expression of P-170 and GST-in and also found a significant relationship (P<0.0001) (Table  VII) . A significant inter-relationship between P-170 or GST-ic (Carr, 1987) . In the present study, we demonstrate that NSCLC of smokers are more frequently resistant than tumours of non-smokers. Seventynine per cent of the tumours of smokers were resistant, whereas only 50% of the tumours of non-smokers revealed resistance. These results are significant (P = 0.007). Identical results were obtained when the analysis was restricted to patients with epidermoid lung carcinomas. In contrast, we found no relationship between doxorubicin-resistance in vitro and smoking for adenocarcinomas of the lung. This may be expected because adenocarcinomas are less frequently associated with smoking than are epidermoid lung carcinomas (Gould & Warren, 1989) .
Until now, the mechanisms for the resistance of lung tumours were unknown but might be multifactorial. Interestingly, there exists a remarkable parallel between the biochemical changes with carcinogen resistance and multidrugresistance. Thorgeirsson et al. (1987) and Fairchild et al. (1987) reported that multidrug-resistance gene transcripts are elevated in preneoplastic and neoplastic nodules in the rat liver during carcinogenesis induced according to the protocol of Solt-Faber (Solt & Faber, 1976) . We also used a model of chemical carcinogenesis in which only one carcinogen, Nnitrosomorpholine, was administered and investigated whether overexpression of P-glycoprotein also takes place in hepatocellular carcinomas (Volm et al., 1990b) . As shown by our experiments, the overexpression of the multidrug-resistance gene is apparent in hepatocellular carcinomas even after withdrawal of the carcinogen. It seems that the multidrugresistance gene belongs to a programmed set of detoxifying mechanisms that is also expressed during carcinogenesis and might be important for lung tumours caused by smoking.
In the past few years several mechanisms for the development of multidrug resistant cell lines in vitro have been identified, for instance overexpression of P-glycoprotein (P-170), glutathione S-transferase-c (GST-ic) and reduction of DNA topoisomerase II (Topo II). P-170 appears to function as a transporter which extrudes a broad spectrum of compounds from the cell (Gottesman & Pastan, 1988) . Glutathione S-transferases represent a family of isoenzymes which conjugate glutathione with various xenobiotics and may play a role in detoxification. Topo II induces double strand breaks during the DNA replication and downregulation of Topo II activity circumvents cytotoxic effects. There are some hints that these detoxifying systems may share common regulatory elements. In the present study we investigated the overexpression of P-170, GST-ic and Topo II in NSCLC and its relationship to doxorubicin-resistance in vitro and smoking habits of the patients. We found a significant relationship between the overexpression of P-170 or GST-ir , and resistance of the tumours or smoking habits of the patients (P<0.0001). The overexpression of these proteins are more frequent in resistant NSCLC and in tumours of smokers. In contrast, we did not find an association of Topo II to either drug resistance of tumours or smoking habits of the patients. Thus, Topo II expression is not linked with resistance of NSCLC of smokers.
In the present study, 44 out of 94 non-small cell lung carcinomas ( = 47%) revealed an expression of P-170. Interestingly, many tumours show a weak immunostaining for P-170. We could not find differences between low levels and higher levels of P-170 with regard to our resistance-results in vitro. This indicates that low levels of P-170 are sufficient to produce a resistance phenotype. This also demonstrates the importance of very sensitive detection systems e.g. immunohistochemistry, for assessing P-170 expression in human tumours. Radosevich et al. (1989) found P-170-expressing cells in 100 out of 131 non-small cell lung carcinomas (= 76%) by immunohistochemical techniques. Lai et al. (1989) demonstrated a weak expression of P-glycoprotein mRNA in 14 out of 24 lung tumours (= 58%). In contrast to these results, other authors have only occasionally detected expression of the MDR gene in lung tumours (CordonCardo et al., 1990) . We recently investigated the intrinsic and acquired resistance of human epidermoid lung cancer xenografts grown in nude mice and found a correlation between expression of P-170 and degree of resistance (Volm et al., 1988b . As shown by Lai et al. (1989) expression of MDR1 RNA of lung cancers was not significantly different from that of corresponding normal lung tissue samples. In own analyses we also found no differential expression of P-170 and MDR1 RNA between normal lung tissue and lung cancers in a limited number of probes (data not shown).
In the present study we correlated the expression of P-170
and GST-i and found a significant correlation (P<0.0001). Cowan et al. (1986) reported that P-170 and GST-ic are both overexpressed in doxorubicin-resistant MCF-7 cells. Burt et al. (1988) demonstrated that transformation of rat liver cells with v-H-ras or v-raf oncogenes results in a MDR-phenotype and an elevated expression of the MDR-1 and the GST-i gene. Keith et al. (1990) found a weak correlation between expression of MDR1 and GST-i in human breast cancer samples suggesting that common mechanisms may be involved. To determine if there is an association between GST-i and MDR1 expression in human leukaemia, Holmes et al. (1990) have investigated their expression in haemopoietic cells of untreated and treated patients. They found no significant correlation in patients with myelodysplastic syndrome or in patients with acute myeloblastic leukaemia, but a positive association between GST-i and MDR1 expression in patients with chronic lymphatic leukaemia. In own experiments we have observed a correlation between GST-i and MDR1 expression in samples of human kidney carcinoma but not in human leukaemia or in breast cancer (Efferth, T., Mattern, J., Volm, M; in preparation) . This indicates that the co-regulation of resistance mechanisms is not a common feature and might be dependent on the tumour type. In fact, other authors did not find a co-expression of P-170 and GST-ir. Cole et al. (1990) described a doxorubicin-resistant small-cell lung cancer cell line (H 69 AR) with elevated activities of GST-i but without overexpression of P-170. In earlier investigations we have analysed doxorubicin-and daunomycin-resistant sublines of murine Sa 180 and L 1210 which were grown in vivo as ascites. In contrast to the resistant Sa 180 tumour lines which show an overexpression of P-170 and GST and a reduction of Topo II, the resistant L 1210 lines shown only an overexpression of P-170 and the levels of GST and Topo II are unchanged compared with the sensitive parental line (unpublished results). Our knowledge is still sparse as to which factors are responsible for a reguluted co-expression of resistance mechanisms. The results of this study demonstrate that a significant relationship between P-170 and GST-ic in NSCLC exists and that the expression is increased in resistant tumours of smokers. Further investigations concerning this point will deepen our understanding of development of resistance of tumours by carcinogens.
